Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$22.91 +0.4%	$21.66	$15.47 ▼ $36.37	$783.75M	1.26	220,166 shs	876,062 shs
CRNX Crinetics Pharmaceuticals	$29.96 -0.1%	$31.47	$24.10 ▼ $70.00	$2.81B	0.28	817,528 shs	1.64 million shs
KYMR Kymera Therapeutics	$44.12 -3.5%	$37.08	$19.45 ▼ $53.27	$2.87B	2.07	623,734 shs	3.80 million shs
MTSR Metsera	$28.59 -0.4%	$26.70	$12.30 ▼ $37.99	$3.00B	N/A	1.02 million shs	932,237 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	0.00%	-9.16%	+8.07%	+23.90%	+23.50%
CRNX Crinetics Pharmaceuticals	0.00%	-0.66%	-2.06%	-10.67%	-33.11%
KYMR Kymera Therapeutics	0.00%	-3.82%	+49.76%	+61.20%	+47.81%
MTSR Metsera	0.00%	-3.41%	+7.85%	+5.03%	+2,858,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.7727 of 5 stars	3.6	2.0	0.0	0.0	2.0	0.8	0.0
CRNX Crinetics Pharmaceuticals	3.5683 of 5 stars	3.5	0.0	0.0	3.7	2.6	2.5	0.0
KYMR Kymera Therapeutics	2.8017 of 5 stars	4.5	1.0	0.0	0.0	2.9	1.7	0.0
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$40.00	74.60% Upside
CRNX Crinetics Pharmaceuticals	2.91	Moderate Buy	$74.56	148.85% Upside
KYMR Kymera Therapeutics	3.00	Buy	$59.61	35.11% Upside
MTSR Metsera	3.00	Buy	$55.00	92.37% Upside

Current Analyst Ratings Breakdown

Latest AVBP, KYMR, MTSR, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	CRNX Crinetics Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/20/2025	MTSR Metsera	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
6/10/2025	MTSR Metsera	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $62.00
6/3/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
CRNX Crinetics Pharmaceuticals	$1.04M	2,697.26	N/A	N/A	$14.29 per share	2.10
KYMR Kymera Therapeutics	$47.07M	61.04	N/A	N/A	$12.90 per share	3.42
MTSR Metsera	N/A	N/A	N/A	N/A	($2.46) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
CRNX Crinetics Pharmaceuticals	-$298.41M	-$3.82	N/A	N/A	N/A	N/A	-30.95%	-28.12%	8/6/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest AVBP, KYMR, MTSR, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/12/2025	Q1 2025	MTSR Metsera	N/A	-$1.03	N/A	-$1.03	N/A	N/A
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.34	14.34
CRNX Crinetics Pharmaceuticals	N/A	22.53	22.53
KYMR Kymera Therapeutics	N/A	8.49	8.49
MTSR Metsera	N/A	6.55	6.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
CRNX Crinetics Pharmaceuticals	98.51%
KYMR Kymera Therapeutics	N/A
MTSR Metsera	N/A

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
CRNX Crinetics Pharmaceuticals	6.00%
KYMR Kymera Therapeutics	16.01%
MTSR Metsera	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
CRNX Crinetics Pharmaceuticals	210	93.63 million	88.01 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A

AVBP, KYMR, MTSR, and CRNX Headlines

Recent News About These Companies

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Nasdaq

June 26, 2025 | nasdaq.com

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

June 24, 2025 | zacks.com

Metsera (NASDAQ:MTSR) Trading Down 6.3% - What's Next?

June 23, 2025 | marketbeat.com

Wells Fargo & Company Begins Coverage on Metsera (NASDAQ:MTSR)

June 22, 2025 | americanbankingnews.com

Wells Fargo Initiates Coverage of Metsera (MTSR) with Overweight Recommendation

June 20, 2025 | msn.com

Metsera (NASDAQ:MTSR) Coverage Initiated by Analysts at Wells Fargo & Company

June 20, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Trading 6.4% Higher - Still a Buy?

June 18, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Shares Gap Up - Time to Buy?

June 16, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Shares Down 5.2% - Time to Sell?

June 13, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Shares Up 4.5% - Time to Buy?

June 12, 2025 | marketbeat.com

Promising Results Of Amylin Analogs In Obesity: Metsera Case Review

June 12, 2025 | seekingalpha.com

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results

June 11, 2025 | msn.com

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med

June 11, 2025 | medcitynews.comM

Cantor Fitzgerald Estimates Metsera FY2026 Earnings

June 11, 2025 | marketbeat.com

Metsera extends gains after early-stage trial data for obesity therapy

June 10, 2025 | msn.com

Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating

June 10, 2025 | msn.com

Metsera (NASDAQ:MTSR) Shares Gap Up After Analyst Upgrade

June 10, 2025 | marketbeat.com

Guggenheim Issues Positive Forecast for Metsera (NASDAQ:MTSR) Stock Price

June 10, 2025 | marketbeat.com

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 10, 2025 | globenewswire.com

Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

June 9, 2025 | finanznachrichten.de

Metsera shares soar on positive amylin candidate trial results

June 9, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks

AVBP, KYMR, MTSR, and CRNX Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$22.91 +0.10 (+0.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$23.25 +0.34 (+1.48%)

As of 04:00 AM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Crinetics Pharmaceuticals NASDAQ:CRNX

$29.96 -0.03 (-0.10%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$70.00 +40.04 (+133.64%)

As of 04:00 AM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Kymera Therapeutics NASDAQ:KYMR

$44.12 -1.59 (-3.48%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$46.62 +2.50 (+5.67%)

As of 04:17 AM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Metsera NASDAQ:MTSR

$28.59 -0.12 (-0.42%)

As of 06/27/2025 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time